Therefore we hypothesized that ER+ tumors with high levels of RelA are likely to be restrained by the tumor-suppressive RelA-IRF1-CDK4 axis while RelA expression levels may have little impact on the other subtypes of breast tumors. The gene discussed is CDK4; the disease is breast neoplasm.